| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
TRANSLATIONAL PHYSIOLOGY
1Department of Pharmacology, National University of Singapore, Singapore 119260; 2Department of Physiology and Pathophysiology, Key Laboratory of Molecular Medicine of The Ministry of Education, Fudan University Shanghai Medical College, Shanghai 200032, China; 3Division of Cardiothoracic Surgery, National University Hospital, Singapore 117597; 4Drug Metabolism and Pharmacokinetics, Aventis Pharma, Paris 94400, France; 5Disease Group Cardiovascular, Aventis Pharma, 65926 Frankfurt; and 6Innere Medizin III, Universität des Saarlandes, 66421 Homburg/Saar, Germany
Submitted 7 May 2003 ; accepted in final form 9 November 2003
Urotensin II (UII) is a vasoactive peptide that has recently emerged as a likely contributor to cardiovascular physiology and pathology. Acute infusion of UII into nonhuman primates results in circulatory collapse and death; however, the exact cause of death is not well understood. This study was undertaken to elucidate the mechanism underlying the fatal cardiovascular event on UII application in vivo in nonhuman primates. To this end, cynomolgus monkeys (n = 4) were anesthetized and tracheal intubation was performed. One internal jugular vein was cannulated for administration of drugs, and one femoral artery for recording of blood pressure and heart rate using a transonic pressure transducer. Cardiac parameters were not significantly changed after administration of 0.003 nmol/kg human UII. A bolus of human UII (0.03 nmol/kg) caused a decrease of heart rate (HR) (13%), mean blood pressure (MBP) (18%), and first-order derivative of left ventricular pressure (dP/dt) (11%). Carotid and coronary blood flow were reduced by 9% and 7%, respectively; 0.3 nmol/kg of human UII resulted in a further reduction of HR (50.3%), MBP (65%), dP/dt (45%), carotid (38%), and coronary blood flow (30%), ultimately leading to cardiovascular breakdown and death. Pulmonary pressure, however, was increased by 30%. Plasma histamine levels were found to be unaffected by administration of UII. Our results indicate that systemic administration of human UII has negative inotropic and chronotropic effects and reduces total peripheral resistance ultimately leading to severe myocardial depression, pulmonary hypertension, and fatal circulation collapse in nonhuman primates. We suggest that successful design of UII antagonists might offer a new therapeutic principle in treating cardiovascular diseases.
cardiac contractility; blood pressure; pulmonary hypertension
This article has been cited by other articles:
|
|
 |
|
  C. Zoccali, F. Mallamaci, F. A. Benedetto, G. Tripepi, P. Pizzini, S. Cutrupi, and L. Malatino Urotensin II and Cardiomyopathy in End-Stage Renal Disease Hypertension, February 1, 2008; 51(2): 326 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Z. Zhu, Z. J. Wang, P. Ho, Y. Y. Loke, Y. C. Zhu, S. H. Huang, C. S. Tan, M. Whiteman, J. Lu, and P. K. Moore Hydrogen sulfide and its possible roles in myocardial ischemia in experimental rats J Appl Physiol, January 1, 2007; 102(1): 261 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Z. Zhu, C. L. Chong, S. C. Chuah, S. H. Huang, H. S. Nai, H. T. Tong, M. Whiteman, and P. K. Moore Cardioprotective effects of nitroparacetamol and paracetamol in acute phase of myocardial infarction in experimental rats Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H517 - H524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Gong, Y.-X. Wang, Y.-Z. Zhu, W.-W. Wang, M.-J. Wang, T. Yao, and Y.-C. Zhu Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat J Appl Physiol, December 1, 2004; 97(6): 2228 - 2235. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
